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The plasma protein binding and competitive inhibition parameters o f  R ( -  )- and 
S(  + )-ibuprofen were determined in vivo in 12 healthy subjects. Subjects participated in a 
4 x 4  Latin square design in which oral solutions o f  drug were administered as 
300 mg R ( - )-ibuprofen, 300 mg S ( + )-ibuprofen, 300 mg R ( - )- + 300 mg S ( + )-ibuprofen, 
and 300 mg R ( - )- + 600 mg S ( + )-ibuprofen. Unlabeled ibuprofen enantiomers were quan- 
titated using a stereospecific reversed-phase H P L C  assay, and plasma protein binding 
experiments were performed using radiolabeled 14C-enantiomers and an ultrafiltration method at 
37C. At  therapeutic drug concentrations, the protein binding o f  each enantiomer was greater 
than 99 %. Furthermore, the binding of  ibuprofen enantiomers was stereoselective and mutually 
competitive, as well as nonlinear. The bound-free data were fi t ted to a model in which the non- 
linearity of  plasma protein binding and competition between enantiomers for  binding sites could 
be accommodated. There were substantial differences in the affinity o f  ibuprofen enantiomers for  
protein binding sites (RP2 = 0.358 +_ 0.185 vs. SP2 = 0.979 +_ 0.501 I~g/m# X +_ SD) but no 
differences in their binding capacity (RP ! = 160 ++ 86 vs. SP1 = 161 + 63 #g/ml). Although 
statistically significant, the differences in competitive inhibition parameters were more modest 
(SKI = 0.661 + 0,363 vs. RKI = 0.436 • 0.210 #g/ml). As a result, the intrinsic binding (i.e., 
P1/P2) of  R ( - )-ibuprofen was greater than S ( + )-ibuprofen, and the unbound fraction was 
significantly greater for S-enantiomer vs. R-enantiomer after a given dose o f  R-ibuprofen or 
racemate. 
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INTRODUCTION 
Ibuprofen is a prototype nonsteroidal anti-inflammatory drug 
(NSAID) of the arylpropionic acid class and, as such, is used for arthritic 
conditions in addition to its analgesic and antipyretic actions. However, 
despite the predominance of its use and numerous clinical studies, large 
gaps remain in our understanding of ibuprofen's pharmacokinetics and 
pharmacodynamics. Reasons for this lack of understanding reflect the fact 
that ibuprofen is administered as raeemate even though its pharmacologic 
activities are associated primarily with the S(+)-enantiomer (1,2). 
Furthermore, the pharmacokinetics of ibuprofen are complicated by a 
unidirectional R-to-S chiral inversion as well as a stereoselectivity in drug 
disposition and plasma protein binding (3-6). 
It is well recognized that plasma protein binding is a primary determi- 
nant of drug clearance for a compound of low hepatic extraction such as 
ibuprofen, and that differences in protein binding (e.g., as a function of dis- 
ease or displacement) can have profound effects on the total drug concen- 
trations observed in plasma (7, 8). However, human studies concerning the 
stereoselective binding of ibuprofen to plasma proteins are sparse (6, 9, 10) 
and data on the protein binding parameters of R( - )- and S( + )-ibuprofen 
and potential for enantiomeric competition in vivo are generally not 
available. As a result, those studies that have ignored the stereoselective 
aspects of ibuprofen protein binding, and its effect on drug metabolism and 
excretion are for the most part uninterpretable. 
During our preliminary inspection of plasma data from healthy 
subjects in which the stereoselective kinetics of chiral inversion were to be 
evaluated, we observed that the protein binding of ibuprofen enantiomers 
appeared to be stereoseleetive and competitive, as well as nonlinear. Given 
the importance of this finding, we report here in detail the in vivo plasma 
protein binding parameters of each ibuprofen enantiomer alone and in the 
presence of its optical antipode. 
METHODS 
Materials 
Unlabeled R(-)-ibuprofen (Lot No. 25965; >~99% chemical purity, 
HPLC/UV) and unlabeled S(+)-ibuprofen (Lot No. 25966; t>99% 
chemical purity, HPLC/UV) were available as sterile oral solutions of each 
enantiomer alone (25 mg/ml). Radiolabeled R(-) [propionic  aeid-3-14C]- 
ibuprofen (Lot No. 91-330-92-04; specific activity, 272pCi/mg; ~>99% 
radiochemical purity, HPLC/Radiodeteetor) and radiolabeled S (+ )  
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[propionic acid-3-~4C]-ibuprofen (Lot No. 91-330-92-03; specific activity, 
255/tCi/mg; ~>99% radiochemical purity, HPLC/Rad iode tec to r )were  
available in ethanol at 534#Ci/ml and 6881zCi/ml, respectively. Both 
unlabeled and radiolabeled enantiomers of ibuprofen were kindly donated 
by The Upjohn Company (Kalamazoo, MI). 
Study Design 
Selected for this study were 12 healthy subjects (Table I), 6 male and 
6 female, between 20-29 years of age, and with a body weight within 
_+15% of ideal values. Subjects were judged healthy, as determined by 
medical history, physical examination, and standard laboratory tests. In 
addition, subjects were nonsmokers and were medication- and alcohol-free 
during the study period. No subject was taking any known enzyme- 
inducing or -inhibiting agent within 30 days of the study. All subjects were 
fully informed of the nature of the study and signed an informed consent 
form approved by the Committee to Review Grants for Clinical Research 
and Investigation Involving Human Beings of the University of Michigan 
Medical School. This study was performed in the General Clinical 
Research Center of the University of Michigan Hospitals. 
Subjects participated in a 4 x 4 Latin square design in which ibuprofen 
was administered as enantiomer and as admixtures of varying proportions. 
Subjects were required to fast for at least 10 h prior to and for 4 h after 
each dose. Standard clinic meals including caffeine-free beverages were 
provided 4 and 10 h after dosing. No food or beverage other than water 
was consumed by the subjects except during the designated meal time. 
Table 1. Clinical Data of Healthy Subjects 
Age Weight Serum protein Serum albumin 
Subject Gender (years) (kg) (g %) (g %) 
1 M 20 64.8 7.6 4.9 
2 F 24 55.9 7.4 4.5 
3 F 23 62.5 7.5 4.4 
4 F 23 50.1 7.5 4.3 
5 F 22 64.0 7.5 4.4 
6 M 21 66.9 8.3 4.9 
7 M 29 66.1 7.5 4.7 
8 M 20 79.9 7.8 4.7 
9 F 25 76.1 7.0 4.2 
10 M 25 90.1 7.7 4.6 
11 F 25 56.7 7.4 4.5 
12 M 23 82.3 8.1 5.1 
JT(__+ SD) 23 (3) 68.0 (11.9) 7.6 (0.3) 4.6 (0.3) 
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During the study, each subject recei#ed the following treatments as single 
oral doses with at least a 7-day washout period between each treat- 
ment: 300 mg R(-)-ibuprofen [300R], 300 mg S(+)-ibuprofen [300S], 
300 mg R( - )- + 300 mg S( - )-ibuprofen [300R + 300S], and 309 mg R( - )- 
+600mg S(+)-ibuprofen [300R+600S]. Blood was drawn from a 
cephalic vein via an indwelling heparinized catheter (10U/ml) and 
deposited into tubes containing EDTA. Seven milliliters of blood were 
drawn prior to dosing and at 0.75, 1.5, 14, and 24h after dosing. Ten 
milliliters of blood were drawn at 0.25, 0.50, 1, 2, 3, 4, 6, 8, 10, and 12 h 
after dosing. Plasma was harvested soon after collection, immediately 
frozen, and stored at ~< -20C until analyzed. Aliquots of plasma obtained 
from the 10-ml blood samples were used in the plasma protein binding 
determinations. 
Analytical Methods 
Unlabeled ibuprofen enantiomers were quantitated in plasma using a 
stereospecific reversed-phase HPLC assay with ultraviolet detection (11) 
after minor modifications. Changes from the original procedure included 
the use of S-flurbiprofen as the internal standard and expanding the upper 
end of the concentration range from 20 to 50/~g/ml. The assay was 
validated from 0.5 to 50 pg/ml, and quality control samples (1.00, 4.01, and 
15.3 #g/ml of each enantiomer) were run over a 3-day period. Overall, the 
precision (% CV) and accuracy (% bias) of the assay were ~<14.2 and 
7.6 %, respectively. 
Radioactive measurements of 14C-ibuprofen enantiomers were per- 
formed on an LS 6000SC liquid scintillation counter (Beckman Instruments, 
Fullerton, CA) after mixing appropriate aliquots of plasma (0.1 ml) or 
ultrafiltrate (0.2ml) with 4.5 ml of Ready Safe T M  scintillation cocktail 
(Beckman Instruments, Fullerton, CA). An external standard method was 
used for quench correction with a counting time of 20 rain or < 2 % error. 
Protein Binding 
The in vivo binding of R( - )- and S( + )-ibuprofen to plasma proteins 
were determined by an ultrafiltration method. Samples were prepared by 
adding 8 #1 of radiolabeled ibuprofen enantiomer (after appropriate dilu- 
tion with methanol) to 0.75 ml of plasma so that counts were obtained in 
the region of 110,000 dpm/ml. A 0.6 ml aliquot was then introduced into a 
disposable Centrifree T M  Micropartition System (Amicon Division, Beverly, 
MA) which utilizes a YMT ultrafiltration membrane (molecular weight 
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cutoff, ca. 30,000), and the plasma sample was centrifuged at 1800 x g in a 
fixed-angle rotor for 20 min at 37C. Under these conditions, approximately 
0.25 ml of ultrafiltrate was obtained. Suitable aliquots of ultrafiltrate and 
prefiltered plasma were then subjected to liquid scintillation counting 
(LSC), as described above. Initial estimates for the unbound fraction were 
calculated as the ratio of ibuprofen enantiomer (dpm/ml) in ultrafiltrate 
and plasma, respectively. Unbound concentrations of ibuprofen enantiomer 
were then calculated as the unbound fraction multiplied by its respective 
total concentration of unlabeled drug in the original plasma sample; bound 
concentrations of ibuprofen enantiomer were calculated as the difference 
between total and unbound concentration in the original plasma sample. 
It should be appreciated that each plasma sample was analyzed on 
two separate occasions, once with radiolabeled R ( -  )-ibuprofen and once 
with radiolabeled S(+)-ibuprofen. Preliminary mass balance studies 
indicated that ibuprofen enantiomers were not adsorbed to the membrane 
or ultrafiltration device and that leakage of plasma proteins was < 0.005 %, 
as determined using protein assay reagent (Bio-Rad Laboratories, 
Hercules, CA), human serum albumin standards (Sigma Chemical Co., 
St. Louis, MO), and the Bradford method (12). An additional purity check 
of the radiolabeled enantiomer was also made in which seven plasma 
standards (at 100 #g/ml for each enantiomer of ibuprofen plus radiolabeled 
drug) were subjected to this ultrafiltration method, and ultrafiltrate and 
prefiltered plasma were subsequently analyzed by LSC and by HPLC (13). 
Mean values (+ SD) for the unbound fraction were 0.833 % (+0.019) and 
0.897% (_+0.091) for R(-)-ibuprofen after LSC and HPLC, respectively; 
the unbound fractions were 0.956% (_+0.070) and 0.889% (_+0.101) for 
S(+)-ibuprofen after LSC and HPLC, respectively. These values were 
within + 8 % of each other, and were not significantly different (paired or 
unpaired t test; e = .05). 
Data Analysis 
Data were pooled for each subject from the four treatment groups 
studied. As a result, 23 to 29 data pairs were available from three treat- 
ments for the bound vs. free plasma concentrations of R( - )-ibuprofen (i.e., 
300R, 300R+ 300S, and 300R+600S), and 32 to 38 data pairs were 
available from four treatments for the bound vs. free plasma concentrations 
of S( + )-ibuprofen (i.e., 300R, 300S, 300R + 300S, and 300R + 600S). In 22 
out of 24 cases, the bound-free data were best fitted to a protein binding 
model that incorporates a single Langmuir term plus a competitive 
inhibition term such that 
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RP1 9 R C F  
R C B =  (1) 
R P 2  . (1 + S C F / S K I )  + R C F  
SP1 9 S C F  
S C B  = (2) 
S P 2 .  ( 1 + R C F / R K I )  + S C F  
R C B  and R C F  are the respective bound and free plasma concentrations of 
R( - )-ibuprofen, RP1 and R P 2  are binding parameters of R( - )-ibuprofen, 
S C B  and S C F  are the respective bound and free plasma concentrations of 
S( + )-ibuprofen, SP1 and SP2 are binding parameters of S( + )-ibuprofen, 
R K I  is the competitive inhibition parameter for R-enantiomeric effects on 
S-enantiomer binding, and S K I  is the competitive inhibition parameter for 
S-enantiomeric effects on R-enantiomer binding. However, in 2 out of 24 
cases, the bound-free data of R(-)-ibuprofen were best fitted to a protein 
binding model that incorporates a single linear term (i.e., R P 1 / R P 2 )  plus 
a competitive inhibition term such that 
R P 1 / R P 2 .  R C F  
R C B  - ( 3 )  
1 + S C F / S K I  
Binding parameters were obtained from Eqs. (1), (2), and (3) using the 
nonlinear least-squares regression program MINSQ (14) and a weighting 
factor of unity. In Eqs. (1) and (3), R C B  was the dependent variable and 
R C F  and S C F  were the independent variables. In Eq. (2), S C B  was the 
dependent variable and S C F  and R C F  were the independent variables. The 
quality of the fit was determined by evaluating the coefficient of determina- 
tion, the standard deviation of parameter estimates and data, and by the 
visual inspection of residuals. Other protein binding models were attempted 
(e.g., competitive Langmuir term plus a linear term). However, the 
additional complexity of the models were beyond what the in vivo data 
would allow. 
To compensate for random fluctuations in the ultrafiltration data, 
fitted values of unbound enantiomer, R C F  (or SCF)  could be obtained by 
finding the positive root of quadratic Eqs. (4) and (5) below for a given 
value of S C F  (or RCF)  and the respective total concentration of 
R-enantiomer, R C P  (or S-enantiomer, S C P )  in the original plasma sample 
(15). As such 
R C F  2 + [RP1 + R P 2 .  (1 + S C F / S K I )  - R C P ]  . R C F  
- R P 2 .  (1 + S C F / S K I ) .  R C P  = 0 (4) 
S C F  2 + [ SP1 + S P 2 .  (1 + R C F / R K I )  - S C P ]  . S C F  
- S P 2 .  (1 + R C F / R K I ) .  S C P = O  (5) 
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for those cases in which protein binding was nonlinear and competitive, 
i.e., corresponds to Eqs. (1) and (2). For those cases in which protein bind- 
ing was linear and competitive, i.e., corresponds to Eq. (3), fitted values of 
unbound R-enantiomer could be calculated in a simpler fashion as 
RCF= RCP (6) 
Reline2 
1+ 
1 + SCF/SK1 
These fitted unbound concentrations (RCF and SCF) were used for 
subsequent calculations of area under the curve and for final estimates of 
the unbound fraction (individual and time-averaged). Area under the 
unbound plasma concentration-time curve for R ( -  )- and S( + )-ibuprofen 
(R.AUC, u and S.AUC, u) was calculated using a combination of the linear 
and log-trapezoidal rules, extrapolated to infinity by CFlast/2n. CFlast is 
the last measurable unbound plasma concentration and 2n is determined 
by linear regression of data points from the log-linear terminal phase. Area 
under the total plasma concentration-time curve (R.A UC and S.A UC) was 
determined in an analogous manner using total concentrations of ibuprofen 





0 . 8  
0.6" o o 













Total Concentration (mcg/ml) 
Fig. 1. Relationship between percentage unbound and total 
plasma concentration of ibuprofen enantiomers, as determined in 
vitro using spiked plasma samples of each enantiomer alone and 
an ultrafiltration method at 37C. 
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and S(+)-ibuprofen (R.Fu and S.Fu) was calculated as the AUC, u/AUC 
ratio of each enantiomer. 
In this analysis, no correction was made for the contribution of label 
to the total plasma concentration of ibuprofen enantiomer. This was unne- 
cessary since the radiolabeled enantiomer (0.2/~g/ml) was negligible in rela- 
tion to the total plasma concentration at which nonlinear protein binding 
becomes important (i.e., CP >1 15 pg/ml; Fig. 1). This finding was consistent 
with our in vivo data as well as with observations by other investigators 
(6). Further, this method of data analysis resulted in A UC (and Fu) deter- 
minations that were, on average, within 2 and 5 % of those values obtained 
with nonfitted data for R ( -  )-ibuprofen and S( + )-ibuprofen, respectively. 
Data are reported as mean (•  unless otherwise indicated. For 
each enantiomer, statistical differences were determined between treatments 
(300R, 300R + 300S, 300R + 600S for R ( -  )-ibuprofen; 300R, 300S, 
300R + 300S, 300R + 600S for S( + )-ibuprofen) using ANOVA for a Latin 
square study, with treatments, periods, and subjects as fixed effects 
(~ = .05). Pairwise comparisons were then made using Tukey's test. Signifi- 
cant differences were determined between enantiomers using a paired t test 
(~ = . 0 5 ) .  
RESULTS 
In evaluating the plasma protein binding data of ibuprofen enan- 
tiomers, it was observed that the bound-free relationship Of R ( - ) -  
ibuprofen was substantially shifted to the right as the amount of 
S-enantiomer increased (Fig. 2, top panel). A similar relationship was 
observed for S( + )-ibuprofen while in the presence of increasing amounts 
of R ( -  )-enantiomer, however, the shift was less pronounced (Fig. 2, bot- 
tom panel). This interaction was consistent for both enantiomers in all 12 
subjects and appeared to be one of a competitive nature. The observed but 
smaller shift for S( + )4buprofen data is a consequence of this particular 
study design in which R-enantiomer doses were not as varied as for the 
S-enantiomer. These figures also demonstrate the nonlinear protein binding 
of ibuprofen enantiomers after a typical 600-mg dose of racemate. 
Based on this observation, ibuprofen enantiomers were fitted to a 
model in which the nonlinearity of plasma protein binding and competition 
between enantiomers for binding sites could be accommodated. As shown 
in Table II, this model was able to provide estimates for the binding 
parameters of R( - )-ibuprofen in 10 out of 12 subjects, and for the binding 
parameters of S(+ )-ibuprofen in 12 out of 12 subjects. However, in 2 sub- 
jects the binding parameters of R( - )-ibuprofen were better estimated using 
a linear model with a competitive inhibition term. Regardless, the data 
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Fig. l Bound-free relationship of R(-)- ibuprofen plasma 
concentrations in a representative healthy subject, as determined 
in vivo using experimentally derived plasma samples and an 
ultrafiltration method at 37C (top panel); bound-free relationship 
of S(+)-ibuprofen plasma concentrations in the same healthy 
subject (bottom panel). Subjects received each treatment accord- 
ing to a Latin square design in which oral solutions of drug 
were administered as 300 mg R(-)- ibuprofen [300R], 300 mg 
S( + )-ibuprofen [300S], 300 mg R( - )- + 300 mg S( + )-ibuprofen 
E300R + 300S], and 300 nag R ( -  )- + 600 nag S( + )-ibuprofen 
[300R + 600S]. 
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Table II. Plasma Protein Binding and Competitive Inhibition Parameters of R ( - ) -  and 
S( + )-Ibuprofen 
Subject 
Binding parameters of R( - )-ibuprofen a Measures of fit b 
RP1 (/zg/ml) RP2 (/~g/ml) SKI (/tg/ml) RP1/RP2 r 2 Corr MSC 
1 125 (30) 0.292 (0.083) 0.717 (0.093) 428 .986 .993 4.014 
2 63.8 (6.7) 0.124 (0.020) 1.35 (0.43) 515 .984 .992 3.882 
3 88.6 (9.1) 0,218 (0.031) 1.42 (0,25) 406 .992 .996 4.572 
4 195 (49) 0.362 (0..106) 0.391 (0.027) 539 .990 .995 4.362 
5 303 (184) 0,669 (0.438) 0,332 (0.030) 453 .984 .992 3.917 
6 113 (17) 0.291 (0.056) 0.587 (0.078) 388 ,990 .995 4.329 
7 218 (78) 0.475 (0.206) 0,467 (0.082) 459 .982 .991 3.796 
8 - -  - -  0.548 (0.048) 385 (10) .984 .992 3.986 
9 67.2 (10.2) 0.146 (0.031) 0.773 (0.180) 460 .978 .989 3.579 
10 - -  - -  0.369 (0.046) 442 (15) .971 .985  3.393 
11 280 (110) 0,618 (0.284) 0,483 (0.054) 453 .980 .990 3.672 
12 144 (34) 0.389 (0.107) 0.492 (0.056) 370 .989 .995 4.242 
J ( i S D  160• 0.358• 0.661• 442• 
Binding parameters of S( + )-ibuprofen" 
SPI (pg/ml) SP2 (/tg/ml) RKI (/zg/ml) SP1/SP2 
1 103 (11) 0.533 (0.065) 0,844 (0.453) 193 .993 .997 4,841 
2 114 (10) 0.802 (0.088) 0.789 (0.171) 142 .995 .998 5,070 
3 225 (32) 1.47 (0.23) 0.362 (0.033) 153 .997 .999  5,487 
4 298 (105) 2.18 (0.83) 0.435 (0.082) 137 .988 .994 4.225 
5 104 (10) 0.642(0.077) 0.314(0.032) 162 ,995 .998  5.158 
6 122 (16) 0.563 (0.092) 0.262 (0.040) 217 .989 .994 4.295 
7 146 (24) 0.737 (0.140) 0.262(0.043) 198 ,990 .995 4,437 
8 209 (58) 1.29 (0.38) 0.173 (0.020) 162 .992 .997 4.706 
9 130 (17) 0.708 (0.107) 0.325 (0.053) 184 .993 .997 4.845 
10 123 (16) 0.706 (0.108) 0.376 (0.080) 174 .992 .996 4.734 
11 229 (44) 1.41 (0.29) 0.505 (0.105) 162 .995 .998  5.143 
12 125 (30) 0.710 (0.183) 0.588 (0.292) 176 .982 .992 3.846 
.~_+SD 161 •  0.979• 0.436_+0.210 172_+24 
SignificancC p = 0.9959 p = 0.0066 p = 0.0481 p < 0.0001 
%ralues in parentheses represent the standard error of individual parameter estimates. 
br2 is the coefficient of determination, Corr is the correlation between observed and predicted 
bound concentrations of ibuprofen enantiomer, and MSC is the Model Selection Criterion 
(14). 
cStatistical differences (i.e., RP1 vs. SPI, RP2 vs. SP2, SKI vs. RKI, and RP1/RP2 vs. 
SP1/SP2) were determined by paired t test. 
w e r e  d e s c r i b e d  r e a s o n a b l y  well  overa l l ,  as i n d i c a t e d  b y  t he  m e a s u r e s  of  lit  
a n d  s t a n d a r d  d e v i a t i o n s  of  t he  e s t i m a t e d  p a r a m e t e r s  s h o w n  in  T a b l e  II .  O n  
ave rage ,  t h e r e  were  s u b s t a n t i a l  d i f fe rences  in  t he  aff ini ty  of  i b u p r o f e n  e n a n -  
t i o m e r s  for  p r o t e i n  b i n d i n g  s i tes  ( R P 2 = 0 . 3 5 8  vs. SP2=O.9791~g/ml; 
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SPl=1611~g/ml; p=0.9959).  Although significant, the differences in 
competitive inhibition parameters were more modest (SKI=0.661 vs. 
RKI = 0.436/lg/ml; P = 0.0481 ). As a result, under linear conditions and in 
the absence of a competitor, the intrinsic binding of R( - ) - ibuprofen  was 
two- to threefold greater than that of S( + )-ibuprofen (RP1/RP2 = 442 vs. 
SP1/SP2 = 172; p < 0.0001 ). 
In Table III, areas under the curve for unbound enantiomer (AUC,u) 
and values for the time-averaged unbound fraction (Fu) are provided with 
respect to the actual treatments administered. As shown in this table, the 
range of values for R.A UC, u were very similar between the three treatments 
in which R( - ) - ibuprofen  could be measured. And as expected, the range 
of values for S.AUC, u increased in a monotonic fashion as increasing 
amounts of S ( +  )-ibuprofen were dosed in these four treatments. Based on 
the A UC,u for both enantiomers, the range and mean values for unbound 
fraction also changed as a function of treatment. The unbound fraction of 
R ( -  )-ibuprofen was significantly different between all three pairwise com- 
parisons (p <0.0001), and R.Fu was 38 % greater when administered as 
300R + 600S vs. 300R. This increase reflects the competitive displacement 
of R( - )-ibuprofen by S( + )-ibuprofen since A UC,u values are unchanged 
for R-enantiomer but substantially increased for S-enantiomer. With 
respect to the unbound fraction of S( + )-ibuprofen, five out of six pairwise 
comparisons were significantly different (p < 0.0001), and S.Fu was 29% 
greater when administered as 300R + 600S vs. 300S. In this case, the 
increase is primarily due to the nonlinearity in protein binding produced by 
S-enantiomer since unbound drug concentrations of R( - ) - ibuprofen  do 
not accumulate to the same extent. It is interesting that values for S.Fu are 
the same after 300R and 300S treatments. This probably reflects an effect 
of the competitive inhibitor R( - ) - ibuprofen  being present with the lower 
levels of unbound S-enantiomer in the 300R treatment. And finally, 
the time-averaged unbound fraction of S(+)- ibuprofen was a t  least 
twofold greater than that of R( - ) - ibuprofen  for the three treatments in 
which they were compared. After a typical 600-mg dose of racemate, the 
extent of plasma protein binding was 99.665% for R( - ) - ibuprofen  
(mean RCP<~29.6#g/ml) and 99.242% for S(+)- ibuprofen (mean 
SCP <~ 29.0 #g/ml). 
DISCUSSION 
Ibuprofen is a compound of low hepatic extraction and, as such, 
plasma protein binding is a primary determinant of the drug's total 
clearance and plasma concentrations. Based on theory, changes in the 
unbound fraction would not be expected to change ibuprofen's unbound 
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clearance nor its pharmacologically active unbound species. This outcome 
has been shown experimentally where 15 subjects showed a nonlinear rela- 
tionship between dose and A U C  for total plasma concentrations of drug 
(7). In contrast, the AUC,  u of ibuprofen was linearly related to the dose 
suggesting that oral clearance was dose-independent when based on 
unbound drug. However, this relationship may not hold if the elimination 
pathways of ibuprofen are capacity rate-limited (e.g., due to disease, dis- 
placement, or age). In addition, one must consider the plasma protein 
binding of ibuprofen enantiomers in order to correctly interpret 
dose-response relationships as well as mechanistic data on the drug's 
stereoselective metabolism or chiral inversion kinetics (4, 5). 
Data on the stereoselective aspects of ibuprofen plasma protein 
binding have been rather limited (6, 9, 10), Using an equilibrium dialysis 
method, Evans et al. (10) found the unbound fraction to increase from 
0.296 to 0.461% for R(-)-ibuprofen and from 0.484 to 0.668% for 
S(+ )-ibuprofen as racemic doses were increased from 200 to 1200 mg in 
four healthy male subjects. They also reported that at each dose level, 
the unbound fraction in plasma was significantly greater for the 
S(+)-enantiomer. In a second study (9), these same authors reported the 
unbound fraction of R ( - ) -  and S(+)-ibuprofen as 0.419 and 0.643%, 
respectively, in six healthy male subjects with no effect of cimetidine on 
protein binding. However, it should be appreciated that in these two 
studies, time-averaged values for the unbound fraction were based upon the 
A U C  from only five or six plasma samples. And finally, Evans et al. (6) 
observed that the percentage unbound of each ibuprofen enantiomer was 
concentration-dependent over the therapeutic range and was influenced by 
the presence of its optical antipode. Still, this final observation was 
obtained from in vitro data and, as a whole, no information is available 
on the binding parameters of ibuprofen enantiomers and potential for 
competitive inhibition in the in vivo setting. 
In this study, we provide in vivo data on the extent of plasma protein 
binding as well as estimates for the binding and competitive inhibition 
parameters of R ( - ) -  and S(+ )-ibuprofen in 12 healthy subjects. Consis- 
tent with plasma protein binding studies using ibuprofen racemate (16), 
more than 99% of each enantiomer was protein-bound after therapeutic 
doses of drug. However, stereoselective differences were observed between 
ibuprofen enantiomers in their binding affinity and in their competitive 
inhibitory potential. No difference was observed, however, in the binding 
capacity as a function of chirality. As a result, the intrinsic binding of 
R(-)-ibuprofen was greater than S(+)-ibuprofen, and the unbound 
fraction was significantly greater for S-enantiomer vs. R-enantiomer in all 
relevant treatment comparisons. It is also apparent that the binding of 
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Fig. 3. Three-dimensional plot illustrating the nonlinear binding 
of R(-)-ibuprofen and the competitive displacement by its 
S-enantiomer (top panel); nonlinear binding of S( + )-ibuprofen 
and the competitive displacement by its R-enantiomer (bottom 
panel). Data were simulated for each enantiomer using the mean 
values for binding capacity, and the equilibrium association and 
competitive inhibition constants in Table II. 
either enantiomer is reduced by the presence of its optical antipode. Using 
mean data for the binding capacities, affinity constants, and competitive 
inhibition parameters (Table II), the plasma protein binding for R ( -  )- and 
S( + )-ibuprofen could be summarized in the 3D-plots depicted in Fig. 3 
(top and bottom panels, respectively). After 600 mg or less of ibuprofen 
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racemate, values for the unbound fraction of either enantiomer are 
confined to the gridlines of the lower left quadrant. 
As reviewed by Lin et al. (8), four conditions are required for a signifi- 
cant competitive displacement from plasma proteins to occur. First, the 
displaced drug should be highly protein-bound. Second, the displacer 
should occupy the same binding sites as the displaced drug. Third, the dis- 
placer should have a high affinity for the binding sites (i.e., a tow Ki). And 
finally, the displacer should be present in large amounts relative to its Ki 
value. As demonstrated in this study, all four of these criteria appear to 
have been met with respect to ibuprofen enantiomers. The data are also in 
agreement with a previous study in four healthy male subjects where the 
oral clearance of R(-)- ibuprofen was 29 % greater when administered as 
800-mg racemate than when administered alone as a 400-mg dose (17). 
A comparison of enantiomeric affinity parameters to that of ibuprofen 
racemate is difficult because of the different methods of analysis used by 
investigators (16, 18-20). Nevertheless, our data were remarkably close to 
estimates by Lockwood et al. (16) and Mills et al. (18) in which the equi- 
librium association constant (i.e., KA = 1/P2, reciprocal molar units) was 
reported as 1.76 x l0 s M -1 (in vivo) and 1 x 105 M - j  (in vitro), respec- 
tively. Both studies employed equilibrium dialysis at 37C, 14C-ibuprofen, 
and a Scatchard analysis for one class of binding sites. In contrast, 
Whitlam et al. (19) [KA of 2.73 x 106 M -1 (in vitro)] and Kober and 
Sj6holm (20) [KA of 1.3 x 106M -1 (in vitro)] observed the affinity of 
ibuprofen to be approximately five to ten times greater than our values 
[KA of 5.75 x 105M 1 for R(-)- ibuprofen (in vivo); 2.10 x 105M ~ for 
S(+)-ibuprofen (in vivo)]. Both of these studies employed equilibrium 
dialysis and ~4C-ibuprofen. However, in the one study (19), dialysis was 
performed on defatted solutions of human serum albumin at 37C and a 
Scatchard analysis was performed for two classes of binding sites. In the 
other study (20), dialysis was performed on serum samples at room tem- 
perature and a Scatchard analysis was performed for one class of binding 
sites. A second weaker binding site is thought not to be of any practical 
significance since its detection would not be revealed until very high total 
plasma concentrations of drug had been attained (e.g., > 140/~g/ml) (18). 
Using fluorescence probes and dialysis methods (21) and albumin immobi- 
lized in microparticles (20, 22), ibuprofen has been shown to interact 
specifically and primarily with the diazepam binding site of human serum 
albumin. Our data are compatible with this finding, in which the 
bound-free plasma concentrations of ibuprofen enantiomers were best 
described by a single class of binding sites. Although one would expect the 
protein binding of a highly bound drug like ibuprofen to directly correlate 
with protein or albumin levels in plasma, our data do not show such a 
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corre la t ion .  This  is p r o b a b l y  due  to the h o m o g e n e o u s  a m o u n t s  of p l a s m a  
pro te ins  ( C V <  6 % )  observed  in  the hea l thy  subjects  s tudied.  
In  conc lus ion ,  the p l a sma  p ro te in  b i n d i n g  a n d  compet i t ive  i n h i b i t i o n  
pa rame te r s  of R ( - ) -  a n d  S ( -  ) - ibuprofen  were d e t e r m i n e d  in vivo ila 12 
hea l thy  subjects.  At  the rapeu t i c  d rug  concen t r a t i ons ,  the p ro t e in  b i n d i n g  of 
i bup ro fen  e n a n t i o m e r s  was stereoselective a n d  m u t u a l l y  compet i t ive ,  as 
well as non l inea r .  
A C K N O W L E D G M E N T  
The  a u t h o r s  t h a n k  K a t h l e e n  L i e d h o l m  G o l d b e r g  for her  help with the 
cl inical  aspects  of the study. 
R E F E R E N C E S  
1. S. S. Adams, P. Bresloff, and C. G. Mason. Pharmacological differences between the opti- 
cal isomers of ibuprofen: evidence for metabolic inversion of the (-)-isomer. J. Pharm. 
Pharmacol. 28:256-257 (1976). 
2. A. J. Hutt and J. Caldwell. The importance of stereochemistry in the clinical pharmaco- 
kinetics of the 2-arylpropionic acid nonsteroidal anti-inflammatory drugs. Clin. 
Pharmacokin. 9:371 373 (1984). 
3. R. O. Day, G. G. Graham, K. M. Williams, G. D. Champion, and J. de Jager. Clinical 
pharmacology of non-steroidal anti-inflammatory drugs. PharmacoL Ther. 33:383433 
(1987). 
4. F. Jamali, R. Mehvar, and F. M. Pasutto. Enantioselective aspects of drug action and 
disposition: therapeutic pitfalls, J. Pharm. Sci. "78:695-715 (1989). 
5. M. D. Murray and D. C. Brater. Nonsteroidal anti-inflammatory drugs. Clin. Geriat. Med. 
6:365-397 (1990). 
6. A. M. Evans, R. L. Nation, N. L. Sansom, F. Bochner, and A. A. Somogyi. Stereoselective 
plasma protein binding of ibuprofen enantiomers. Eur. J. Clin. Pharmacol. 36:283-290 
(1989). 
7. G. F. Lockwood, K. S. Albert, W. R. Gillespie, G. G, Bole, T. M. Harkcom, G. J. 
Szpunar, and J. G. Wagner. Pharmacokinetics of ibuprofen in man. I. Free and total 
area/dose relationships. Clin. Pharmacol. Ther. 34:97-103 (1983). 
8. J. H. Lin, D. M. Cocchetto, and D. E. Duggan. Protein binding as a primary determinant 
of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs. Clin. 
Pharmacokin. 12:402432 (1987). 
9. A. M. Evans, R. L. Nation, and L. N. Sansom. Lack of effect of cimetidine on the phar- 
macokinetics of R ( - ) -  and S(+ )-ibuprofen. Br..1. Clin. Pharmacol. 28:143-149 (1989). 
10. A. M. Evans, R. L. Nation, L. N. Sansom, F. Bochner, and A. A. Somogyi. The rela- 
tionship between the pharmacokinetics of ibuprofen enantiomers and the dose of racemic 
ibuprofen in humans. Biopharm. Drug Dispos. 11:507 518 (1990). 
11. R. Mehvar, F. Jamali, and F. M. Pasutto. Liquid-chromatographic assay of ibuprofen 
enantiomers in plasma. Clin. Chem. 34:493496 (1988). 
12. M. M. Bradford. A rapid and sensitive method for the quantitation of microgram quan- 
tities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254 
(1976). 
13. A. Shah and D. Jung. Improved high-performance liquid chromatographic assay of 
ibuprofen in plasma. J. Chromatog. 344:408411 (1985). 
14. MINSQ: Nonlinear Curve Fitting and Model Development, MicroMath Scientific Software, 
Salt Lake City, UT, 1992. 
Plasma Protein Binding of Ibuprofen Enantiomers 161 
15. H. L. Behm and J. G. Wagner. Errors in interpretation of data from equilibrium dialysis 
protein binding experiments. Res. Commun. Chem. Pathol. Pharmacol. 26:145-160 (1979). 
16. G. F. Lockwood, K. S. Albert, G. J. Szpunar, and J. G. Wagner. Pharmacokinetics of 
ibuprofen in man IIl: Plasma protein binding. J. Pharmacokin. Biopharm. 11:469M-82 
(t983). 
17. E. J. D. Lee, K. Williams, R. Day, G. Graham, and D. Champion. Stereoselective disposi- 
tion of ibuprofen enantiomers in man. Br. J. Clin. Pharmacol. 19:669-674 (1985). 
18. R. F. N. Mills, S. S. Adams, E. E. Cliffe, W. Dickinson, and J. S. Nicholson. The 
metabolism of ibuprofen. Xenobiotica 3:589-598 (1973). 
19. J. B. Whitlam, M. J. Crooks, K. F. Brown, and P. Veng-Pedersen. Binding of non- 
steroidal anti-inflammatory agents to proteins-I. Ibuprofen-serum albumin interaction. 
Biochem. PharmacoL 28:675-678 (1979). 
20. A. Kober and I. Sj6holm. The binding sites on human serum albumin for some 
non-steroidal anti-inflammatory drugs. Mol. Pharmacol. 18:421~426 (1980). 
21. G. Sudlow, D. J. Birkett, and D. N. Wade. Further characterization of specific drug 
binding sites on human serum albumin. Mol. Pharmacol. 12:1052-1061 (1976), 
22. I. Sj6holm, B. Ekman, A. Kober, I. Ljungstedt-P~thlman, B. Seiving, and T. Sj6din. 
Binding of drugs to human serum albumin: XI. The specificity of three binding sites as 
studied with albumin immobilized in microparticles. Mol. Pharmacol. 16:767-777 (1979). 
